| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | 0.0063 | 0.9 |
| mRNA | palmostatin B | CTRPv2 | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | ruxolitinib | GDSC1000 | pan-cancer | AAC | 0.0035 | 0.9 |
| mRNA | GSK4112 | CTRPv2 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | GSK690693 | GDSC1000 | pan-cancer | AAC | -0.0032 | 0.9 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.0047 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.0038 | 0.9 |
| mRNA | NPK76-II-72-1 | GDSC1000 | pan-cancer | AAC | -0.0029 | 0.9 |
| mRNA | CP724714 | GDSC1000 | pan-cancer | AAC | -0.0032 | 0.9 |